MedPath

Longitudinal Investigation of Cancer-related Fatigue

Withdrawn
Conditions
Cancer-related Fatigue
Registration Number
NCT03211273
Lead Sponsor
German Cancer Research Center
Brief Summary

In the LIFT study 2000 cancer patients will be recruited at 6 months after diagnosis and extensively surveyed over five years on factors that are associated with fatigue.

Detailed Description

The LIFT study aims to comprehensively investigate characteristics, determinants, and long-term course of fatigue. In addition, information shall be gained on the current state of fatigue treatment and care in Germany and on the needs of affected patients.

Data will be collected by mailed or online questionnaires at 6, 9, and 12 months as well as 2, 3, 4 and 5 years post-diagnosis from 2000 cancer patients. Besides questionnaires on socio-demographic, clinical and patient reported outcomes, saliva samples will be collected in order to gain new insights into biological mechanisms. Moreover, detailed data on screening, diagnosis and counseling as well as therapies offered and administered to reduce fatigue will be surveyed, as well as the patients' state of knowledge, perception and prevailing needs regarding fatigue. Tumor and cancer therapy data will be extracted from the Epidemiological Cancer Registry.

The results of the LIFT study aim to contribute to an improved, evidence-based and individualized treatment to avoid and ease cancer-related fatigue and will further promote patient-oriented offers and treatments.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • ≥ 18 years of age
  • Diagnosed with a primary tumor of breast, ovarian, or colon cancer
  • Time since first diagnosis is 4 - 6 months
  • Having received or currently receiving at least one of the following treatments: surgery, chemotherapy, radiotherapy, hormone therapy, or immune therapy.
  • Able to understand and follow the study protocol.
Exclusion Criteria

• Any additional malignant or unclear neoplasm or carcinoma in situ at or since time of diagnosis of the considered primary tumor

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Impact of fatiguefrom diagnosis to 1 year post-diagnosis

assessed by the Brief Fatigue Inventory (BFI)

Fatigue severityfrom diagnosis to 1 year post-diagnosis

assessed by EORTC QLQ-FA12 (European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire)

State of fatigue managementfrom diagnosis to 1 year post-diagnosis

Questionnaire assessing the adherence to the National Comprehensive Cancer Network (NCCN) guidelines regarding management of cancer-related fatigue

Secondary Outcome Measures
NameTimeMethod
Quality of life functions and symptoms6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed by EORTC QLQ-C30

Body mass index6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

calculated from weight and height

Sleep problems6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed by Pittsburgh Sleep Quality Index (PSQI)

Total physical activity6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed by a questionnaire regarding walking, cycling, and exercise behavior

Depression6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed by Patient Health Questionnaire (PHQ-9)

Diurnal cortisol rhythm1 year post-diagnosis

assessed in saliva

Return to work6, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed by a questions regarding occupational issues

Hot flashes6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed only for women

Anxiety6, 9, 12 months and 2, 3, 4, and 5 years post-diagnosis

assessed by the Generalized Anxiety Disorder Questionnaire (GAD-7)

© Copyright 2025. All Rights Reserved by MedPath